Abstract
Bleomycin, a widely used anti-tumor agent, is well-known to cause single- and double-strand breaks in cellular DNA in vivo and in vitro leading finally to genomic instability of damaged cells. Bleomycin causes an increase of reactive oxygen species resulting in oxidative stress and pulmonary fibrosis. Further, bleomycin induces apoptosis and senescence in epithelial and non-epithelial cells of the lung. Caveolin-1 is a scaffold protein of caveolae, which are particularly abundant in alveolar epithelial type I cells, in endothelial and smooth muscle cells, and in fibroblasts of lung tissue. Caveolin-1 directly interacts with signaling molecules and effects diverse signaling pathways regulating cell proliferation, apoptosis, differentiation and growth. In this review we discuss aspects of bleomycin resistance. We summarize recent data about the effects of bleomycin in terms of lung cell biology and emphasize that bleomycin-induced injury of lung cells is accompanied by altered expression levels of caveolin-1. Caveolin-1 is involved in bleomycin-induced apoptosis and senescence of normal and lung cancer cells. Investigating the role of caveolin-1 may provide new tools for therapeutic interventions in lung disease and for the understanding of tumor biology.
Keywords: Bleomycin, resistance, caveolin-1, apoptosis, senescence, pulmonary fibrosis, lung cancer
Current Cancer Drug Targets
Title: Bleomycin and its Role in Inducing Apoptosis and Senescence in Lung Cells - Modulating Effects of Caveolin-1
Volume: 9 Issue: 3
Author(s): Michael Kasper and Kathrin Barth
Affiliation:
Keywords: Bleomycin, resistance, caveolin-1, apoptosis, senescence, pulmonary fibrosis, lung cancer
Abstract: Bleomycin, a widely used anti-tumor agent, is well-known to cause single- and double-strand breaks in cellular DNA in vivo and in vitro leading finally to genomic instability of damaged cells. Bleomycin causes an increase of reactive oxygen species resulting in oxidative stress and pulmonary fibrosis. Further, bleomycin induces apoptosis and senescence in epithelial and non-epithelial cells of the lung. Caveolin-1 is a scaffold protein of caveolae, which are particularly abundant in alveolar epithelial type I cells, in endothelial and smooth muscle cells, and in fibroblasts of lung tissue. Caveolin-1 directly interacts with signaling molecules and effects diverse signaling pathways regulating cell proliferation, apoptosis, differentiation and growth. In this review we discuss aspects of bleomycin resistance. We summarize recent data about the effects of bleomycin in terms of lung cell biology and emphasize that bleomycin-induced injury of lung cells is accompanied by altered expression levels of caveolin-1. Caveolin-1 is involved in bleomycin-induced apoptosis and senescence of normal and lung cancer cells. Investigating the role of caveolin-1 may provide new tools for therapeutic interventions in lung disease and for the understanding of tumor biology.
Export Options
About this article
Cite this article as:
Kasper Michael and Barth Kathrin, Bleomycin and its Role in Inducing Apoptosis and Senescence in Lung Cells - Modulating Effects of Caveolin-1, Current Cancer Drug Targets 2009; 9 (3) . https://dx.doi.org/10.2174/156800909788166501
DOI https://dx.doi.org/10.2174/156800909788166501 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Clinical Prognostic Value of LRG1 in Esophageal Squamous Cell Carcinoma
Current Cancer Drug Targets Apoptosis in Anthracycline Cardiomyopathy
Current Pediatric Reviews Cullin-RING Ligases as Attractive Anti-cancer Targets
Current Pharmaceutical Design Metastatic Brain Tumors: To Treat or Not to Treat, and with What?
Current Cancer Therapy Reviews Targeting Epigenetic Modifiers in Cancer
Current Medicinal Chemistry Recent Evidence on the Role of Dietary PUFAs in Cancer Development and Prevention
Current Medicinal Chemistry Antisense Strategies in Therapy of Gliomas
Current Signal Transduction Therapy Medicinal Chemistry of Antiviral/Anticancer Prodrugs Subjected to Phosphate Conjugation
Mini-Reviews in Medicinal Chemistry Pharmacogenetics of the Cytochromes P450
Current Topics in Medicinal Chemistry Advances in the use of MOFs for Cancer Diagnosis and Treatment: An Overview
Current Pharmaceutical Design Stem Cells: An Overview of the Current Status of Therapies for Central and Peripheral Nervous System Diseases
Current Medicinal Chemistry Alternative Splicing in Chronic Myeloid Leukemia (CML): A Novel Therapeutic Target?
Current Cancer Drug Targets Radiotracers for Molecular Imaging of Cyclooxygenase-2 (COX-2) Enzyme
Current Medicinal Chemistry Selected Attributes of Polyphenols in Targeting Oxidative Stress in Cancer
Current Topics in Medicinal Chemistry Targeting the BRCA1/2 Tumor Suppressors
Current Drug Targets Synthesis, In Vitro Anticancer, Anti-Inflammatory and DNA Binding Activity of Thiazolidinedione Derivatives
Anti-Cancer Agents in Medicinal Chemistry Validated RP-HPLC Method for the Simultaneous Analysis of Gemcitabine and LY-364947 in Liposomal Formulations
Current Drug Targets Fighting Tumor Cell Survival: Advances in the Design and Evaluation of Pim Inhibitors
Current Medicinal Chemistry Gene Transfer and Drug Delivery with Electric Pulse Generators
Current Drug Metabolism Gene Expression Significance in Personalized Medicine of Non-small Cell Lung Cancer and Gene Expression Analyzing Platforms
Current Drug Metabolism